Historical Timeline
| 1985 | Frank McCormick, Ph.D., begins cancer research program at Cetus Corporation | |
| 1991 | Cetus Corporation merges with Chiron Corporation | |
| 1992 | Onyx Pharmaceuticals is founded by Frank McCormick to discover and develop cancer therapeutics and is spun out of the Cetus and Chiron merger as privately held company | |
| 1993 | Onyx appoints Hollings Renton as the company's first president & CEO | |
| 1994 | Onyx and Bayer HealthCare Pharmaceuticals form collaboration | |
| 1995 | Onyx and Warner Lambert, now Pfizer, form collaboration to develop therapeutics for cell cycle regulation | |
| 1996 |
Frank McCormick leaves Onyx to become head of the University of California, San Francisco Cancer Research Institute Onyx completes IPO and is listed on the Nasdaq under stock symbol ONXX |
|
| 1998 | Onyx and Warner Lambert, now Pfizer, extend collaboration in area of cell cycle regulation | |
| 2000 | BAY 43-9006 (now Nexavar), an oral targeted therapy, enters clinical testing | |
| 2003 | Onyx focuses its efforts solely on the development of BAY 43-9006 and discontinues therapeutic virus program | |
| 2004 | PD 0332991, an oral, cell cycle inhibitor, enters clinical testing | |
| 2005 | Nexavar is approved for the treatment of patients with advanced kidney cancer; the first new drug in more than a decade for this disease | |
| 2007 |
Pivotal kidney cancer study (TARGET) published in The New England Journal of Medicine Nexavar is approved as the first and only targeted therapy for the treatment of patients with unresectable liver cancer |
|
| 2008 |
Hollings Renton retires as chairman and CEO of Onyx Tony Coles, M.D., joins Onyx as president and CEO Pivotal liver cancer study (SHARP) published in The New England Journal of Medicine Onyx acquires ONX 0801, a novel targeted oncology compound in preclinical development Onyx acquires options to license rights to two JAK 2 inhibitors, ONX 0803 and ONX 0805, with potential broad utility in multiple diseases |
|
| 2009 |
Onyx and Bayer report positive results from a Phase 2 trial evaluating Nexavar plus chemotherapeutic agent, capecitabine, in patients with advanced breast cancer Onyx acquires Proteolix Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of patients with cancer and autoimmune diseases |